Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type
Paul Lephart, Michael A. Bachman, William LeBar, Scott McClellan, Karen Barron, Lee Schroeder, Duane W. Newton
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)VirologyPandemicGold standard (test)2019-20 coronavirus outbreakPopulationInternal medicineInfectious disease (medical specialty)Environmental healthDiseaseOutbreakSARS-CoV-2 detection and testingRespiratory viral infections researchSARS-CoV-2 and COVID-19 Research